Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-15T05:44:25.161Z Has data issue: false hasContentIssue false
  • English
  • Français

The Clinical Efficacy of Citalopram in Treatment of Emotional Disturbances in Dementia Disorders a Nordic Multicentre Study

Published online by Cambridge University Press:  02 January 2018

Anna Lena Nyth  and
Carl Gerhard Gottfries
Anna Lena Nyth*
Affiliation:
University of Göteborg, Department of Psychiatry and Neurochemistry, St Jörgen's Hospital, S-422 03 Hisings-Backa, Sweden
Carl Gerhard Gottfries
Affiliation:
University of Göteborg, Department of Psychiatry and Neurochemistry, St Jörgen's Hospital
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

In this multicentre study, the clinical efficacy of citalopram was investigated in 98 patients with moderate AD/SDAT or VD using a combined double-blind and open technique with placebo and citalopram. Analyses were made for each diagnosis after four weeks of double-blind treatment. Patients with AD/SDAT treated with citalopram showed a significant improvement in emotional bluntness, confusion, irritability, anxiety, fear/panic, depressed mood and restlessness. Those improvements were not found after treatment with placebo. There were no significant improvements in patients with VD. No improvements were recorded in motor or cognitive impairment. Citalopram provoked few and comparatively mild side-effects. None of the changes observed during the double-blind withdrawal period were identified as withdrawal symptoms or rebound phenomena.

Type
Papers
Information
The British Journal of Psychiatry , Volume 157 , Issue 6 , December 1990 , pp. 894 - 901
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Andersen, O., Johansson, B. B. & Svennerholm, L. (1981) Monoamine metabolites in successive samples of spinal fluid. Acta Neurologica Scandinavica, 63, 247–254.CrossRefGoogle ScholarPubMed
Andersson, M. (1989) Elderly patients in nursing homes and in home care. Doctoral Thesis, University of Göteborg.Google Scholar
Balldin, J., Gottfries, C-G., Långström, G., et al (1988) Relationship between DST and the serotonergic system. Results from treatments with two 5-HT reuptake blockers in dementia disorders. International Journal of Geriatric Psychiatry, 3, 17–26.CrossRefGoogle Scholar
Bergman, I., Bråne, G., Gottfries, C-G., et al (1983) Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology, 80, 279–283.Google Scholar
Bjerkenstedt, L., Edman, G., Flyckt, L., et al (1985) Clinical and biochemical effects of citalopram, a selective 5–HT reuptake inhibitor – a dose-response study in depressed patients. Psychopharmacology, 87, 253–259.Google Scholar
Bråne, G. & Gottfries, C-G. (1985) Treatment with monoaminergic drugs in Alzheimer's disease and senile dementia. In Proceedings of Two Symposia Held at The Collegium Internationale Neuro-Psychopharmacologicum Nth Congress June 22 and 23, 1984, Florence, Italy (ed. C-G. Gottfries). Bruxelles: Éditions de L'Université de Bruxelles.Google Scholar
Carlsson, A. & Gottfries, C-G. (1986) Neurotransmitter abnormalities in old age dementias. In Proceedings of the Vth South-East European Neuropsychiatric Conference Graz 1983 Google Scholar
(eds H. Leichner & A. Paraschos). Tessaloniki: University Studio Press.Google Scholar
Christensen, P., Thomsen, H. Y., Pedersen, O. L., et al (1985) Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology, 86, 383–385.Google Scholar
Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 90, 131–138.Google Scholar
Fredricson-Overö, K. (1978) Preliminary studies of the kinetics of citalopram in man. European Journal of Clinical Pharmacology, 14, 69–73.Google Scholar
Fredricson-Overö, K. (1982) Kinetics of citalopram in man; plasma levels in patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 6, 311–318.CrossRefGoogle ScholarPubMed
Gottfries, C-G., Bråne, G., Gullberg, B., et al (1982) A new rating scale for dementia syndromes. Archives of Gerontology and Geriatrics, 1, 311–330.Google Scholar
Gottfries, C-G., Adolfsson, R., Aquilonius, S. M., et al (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiology of aging, 4, 261–271.Google Scholar
Gravem, A., Amthor, K. F., Astrup, C., et al (1987) A double-blind comparison of citalopram (Lu 10–171) and amitriptyline in depressed patients. Acta Psychiatrica Scandinavica, 75, 478–486.Google Scholar
Guy, W. (1976) ECDEU assessment manual for psychopharmacology. Clinical Global Impressions (028-CGI), 216–222.Google Scholar
Hardy, J., Adolfsson, R., Alafuzoff, I., et al (1985) Review. Transmitter deficits in Alzheimer's disease. Neurochemistry International, 7, 545–563.Google Scholar
Harenko, A. & Elgen, K. (1984) On a clinical phase II study of citalopram in elderly depressed patients. H. Lundbeck A/S Report. 19/831. Copenhagen: H. Lundbeck A/S.Google Scholar
Hyttel, J. (1982) Citalopram – pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in Neuro-psychopharmacology and Biological Psychiatry, 6, 277–295.Google Scholar
Karlsson, I., Bråne, G., Melin, E., et al (1988) Effects of environmental stimulation on biochemical and psychological variables in dementia. Acta Psychiatrica Scandinavica, 77, 207–213.CrossRefGoogle ScholarPubMed
Lindegaard-Pedersen, O., Kragh-Sörensen, P., Bjerre, M., et al (1982) Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect – a phase II study. Psychopharmacology, 77, 199–204.Google Scholar
Lingjaerde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU side-effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, suppl. 334.Google Scholar
Marcusson, J. O., Alafuzoff, I., Bäckström, I. T., et al (1987) 5-hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Progress in Brain Research, 425, 137–145.CrossRefGoogle ScholarPubMed
Merriam, A., Aronson, M. K., Gaston, T., et al (1988) The psychiatric symptom of Alzheimer's disease. Journal of the American Geriatrics Society, 36, 7–12.Google Scholar
Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 381–382.Google Scholar
Nyth, A-L., Balldin, J., Elgen, K., et al (1987) Behandling med Citalopram vid demens. Normalisering av DST. Nordisk Psykiatrisk Tidskrift, 41, 423–430.CrossRefGoogle Scholar
Reifler, B. V., Larson, E., Teri, L., et al (1986) Dementia of the Alzheimer's type and depression. Journal of the American Geriatrics Society, 34, 855–859.Google Scholar
Sas (1985) SAS user's guide: statistics. Cary, USA: SAS Institute Inc.Google Scholar
Shaw, D., Harris, B., Lloyd, A. T., et al (1986) A comparison of the antidepressant action of citalopram and amitriptyline. British Journal of Psychiatry, 149, 515–517.Google Scholar
Wallin, A., Alafuzoff, I., Carlsson, A., et al (1989) Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurologica Scandinavica, 79, 397–406.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.